Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sleep disturbance in substance use disorders: the orexin (hypocretin) system as an emerging pharmacological target

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Guo R, Vaughan DT, Almeida Rojo AL, Huang YH. Sleep-mediated regulation of reward circuits: implications in substance use disorders. Neuropsychopharmacology. 2022. https://doi.org/10.1038/s41386-022-01356-8.

  2. James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?. Neuropsychopharmacology. 2020;45:717–9.

    Article  Google Scholar 

  3. Mehr JB, Bilotti MM, James MH. Orexin (hypocretin) and addiction. Trends Neurosci. 2021;44:852–5.

    CAS  Article  Google Scholar 

  4. Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. The discovery of suvorexant, the first orexin receptor drug for insomnia. Annu Rev Pharm Toxicol. 2017;57:509–33.

    CAS  Article  Google Scholar 

  5. Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL. et al. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Transl Med. 2022;14:eabn8238

    CAS  Article  Google Scholar 

  6. James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G. Increased number and activity of a lateral subpopulation of hypothalamic orexin/hypocretin neurons underlies the expression of an addicted state in rats. Biol Psychiatry. 2019;85:925–35.

    CAS  Article  Google Scholar 

Download references

Funding

This work was supported by grants from the National Institute on Drug Abuse (R00 045765) and the Busch Biomedical Grant from the Office for Research at Rutgers University.

Author information

Authors and Affiliations

Authors

Contributions

Both UG and MHJ drafted and edited the manuscript.

Corresponding author

Correspondence to Morgan H. James.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gyawali, U., James, M.H. Sleep disturbance in substance use disorders: the orexin (hypocretin) system as an emerging pharmacological target. Neuropsychopharmacol. (2022). https://doi.org/10.1038/s41386-022-01404-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41386-022-01404-3

Search

Quick links